Pooling RT-qPCR testing for SARS-CoV-2 in 1000 individuals of healthy and infection-suspected patients.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
03 11 2020
03 11 2020
Historique:
received:
04
06
2020
accepted:
21
10
2020
entrez:
4
11
2020
pubmed:
5
11
2020
medline:
21
11
2020
Statut:
epublish
Résumé
Severe acute respiratory coronavirus 2 (SARS-CoV-2) testing reagents are expected to become scarce worldwide. However, little is known regarding whether pooling of samples accurately detects SARS-CoV-2. To validate the feasibility of pooling samples, serial dilution analysis and spike-in experiments were conducted using synthetic DNA and nucleic acids extracted from SARS-CoV-2-positive and -negative patients. Furthermore, we studied 1000 individuals, 667 of whom were "healthy" individuals (195 healthcare workers and 472 hospitalized patients with disorders other than COVID-19 infection), and 333 infection-suspected patients with cough and fever. Serial dilution analysis showed a limit of detection of around 10-100 viral genome copies according to the protocol of the National Institute of Infectious Diseases, Japan. Spike-in experiments demonstrated that RT-qPCR detected positive signals in pooled samples with SARS-CoV-2-negative and -positive patients at 5-, 10-, 20-fold dilutions. By screening with this pooling strategy, by the end of April 2020 there were 12 SARS-CoV-2-positive patients in 333 infection-suspected patients (3.6%) and zero in 667 "healthy" controls. We obtained these results with a total of 538 runs using the pooling strategy, compared with 1000 standard runs. In a prospective study, we successfully detected SARS-CoV-2 using 10- to 20-fold diluted samples of nasopharyngeal swabs from eighteen COVID-19 patients with wide ranges of viral load. Pooling sample is feasible for conserving test reagents and detecting SARS-CoV-2 in clinical settings. This strategy will help us to research the prevalence infected individuals and provide infected-status information to prevent the spread of the virus and nosocomial transmission.
Identifiants
pubmed: 33144632
doi: 10.1038/s41598-020-76043-z
pii: 10.1038/s41598-020-76043-z
pmc: PMC7641135
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
18899Références
JAMA. 2020 May 19;323(19):1912-1914
pubmed: 32221579
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Jpn J Infect Dis. 2020 Jul 22;73(4):304-307
pubmed: 32074516
Proc Natl Acad Sci U S A. 2020 Apr 21;117(16):9122-9126
pubmed: 32245814
J Clin Microbiol. 1998 Dec;36(12):3624-8
pubmed: 9817885
Science. 2020 May 1;368(6490):489-493
pubmed: 32179701
Am J Clin Pathol. 2020 May 5;153(6):715-718
pubmed: 32304208
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
J Virol Methods. 2020 Oct;284:113926
pubmed: 32650037
Nature. 2020 Jul;583(7817):504-505
pubmed: 32651561
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
J Med Virol. 1996 Jul;49(3):218-22
pubmed: 8818968
JAMA. 2020 May 19;323(19):1967-1969
pubmed: 32250394
Int J Infect Dis. 2020 Oct;99:397-402
pubmed: 32800855
Euro Surveill. 2020 Apr;25(14):
pubmed: 32290904
J Clin Virol. 2020 Aug;129:104543
pubmed: 32663787
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Lancet. 1999 Jan 30;353(9150):359-63
pubmed: 9950441
Transfusion. 1998 Oct;38(10):905-7
pubmed: 9767739
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
Infect Control Hosp Epidemiol. 2020 Sep;41(9):1105-1106
pubmed: 32299521
AIDS. 2000 Dec 1;14(17):2751-7
pubmed: 11125894